von Delbrück O, Goetzke E, Nagel C
Br J Clin Pharmacol. 1983;16 Suppl 2(Suppl 2):385S-389S. doi: 10.1111/j.1365-2125.1983.tb02314.x.
A long-term study of brotizolam (minimum 4 weeks: maximum 26 weeks) was carried out in hospitalized patients (29 to 95 years) who complained of sleep disturbance. 3.0% of the patients used 0.125 mg, 86.4% used 0.25 mg, and 10.0% used 0.5 mg daily. During the trial there was no evidence of tolerance. There were no symptoms of overdosage, physical and psychological dependency or withdrawal, and there were no interactions with the concurrently prescribed drugs. There were no changes in vital functions, haematology, or in the biochemical investigations of blood or urine which could be attributed to the drug.
对抱怨有睡眠障碍的住院患者（29至95岁）进行了一项关于溴替唑仑的长期研究（最短4周：最长26周）。3.0%的患者每日使用0.125毫克，86.4%的患者每日使用0.25毫克，10.0%的患者每日使用0.5毫克。在试验期间，没有耐受性的证据。没有过量用药、身体和心理依赖或戒断的症状，并且与同时开的药物没有相互作用。没有可归因于该药物的生命功能、血液学或血液或尿液生化检查的变化。
